Using whole-genome sequencing to determine appropriate streptomycin epidemiological cutoffs for Salmonella and Escherichia coli

FEMS Microbiology Letters
Gregory H TysonShaohua Zhao

Abstract

For Enterobacteriaceae such as Salmonella spp. and Escherichia coli, no unified interpretive resistance criteria exist for streptomycin, an epidemiologically important antibiotic. As part of the National Antimicrobial Resistance Monitoring System, we had previously used a minimum inhibitory concentration of ≥ 64 μg mL(-1) as an epidemiological cutoff value (ECV) to define non-wild-type isolates. To identify whether this ECV correlated with genetic determinants of resistance, we performed whole-genome sequencing of 463 Salmonella and E. coli isolates to identify streptomycin resistance genotypes. From this analysis, we found that using a streptomycin resistance breakpoint of ≥ 64 μg mL(-1) classified over 20% of strains possessing aadA or strA/strB resistance genes as wild-type. Therefore, to improve the concordance between genotypic and phenotypic data, we propose reducing the phenotypic cutoff values to ≥ 32 μg mL(-1) for both Salmonella and E. coli, to be used widely as ECVs to categorize non-wild-type isolates.

References

Aug 26, 1998·The American Journal of Cardiology·W R Daley
Apr 2, 1999·Antimicrobial Agents and Chemotherapy·M P Mingeot-LeclercqP M Tulkens
Apr 18, 2001·EMBO Reports·E C BöttgerP Sander
May 18, 2005·The Journal of Antimicrobial Chemotherapy·Marianne Sunde, Madelaine Norström
Apr 29, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J TurnidgeG Kronvall
May 18, 2006·International Journal of Antimicrobial Agents·Geraldine DoranMartin Cormican
Jul 14, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Lourdes Garcia-MiguraFrank M Aarestrup
May 15, 2015·Journal of Clinical Microbiology·Katrine G JoensenFlemming Scheutz
Jul 5, 2015·The Journal of Antimicrobial Chemotherapy·Gregory H TysonShaohua Zhao

❮ Previous
Next ❯

Citations

Jan 18, 2017·Expert Review of Molecular Diagnostics·W Michael DunneAlex Van Belkum
Jul 7, 2016·Antimicrobial Agents and Chemotherapy·Patrick F McDermottShaohua Zhao
Dec 21, 2016·Antimicrobial Agents and Chemotherapy·Gregory H TysonPatrick F McDermott
Feb 5, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Qi FengGanwu Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Comptes rendus de l'Académie Bulgare des sciences : sciences mathématiques et naturelles
V Zlatev
© 2022 Meta ULC. All rights reserved